Pfizer's $10 Billion Bet on a Shot You Only Take Once a Month
After burning $10 billion on a Metsera buyout and years of obesity drug failures, Pfizer's monthly weight-loss shot just posted Phase 2 numbers that beat Wegovy's early benchmarks, with 75% fewer injections. The weight-loss curve still hadn't plateaued.
Nobody expected Pfizer to show up to the obesity party like this.
After years of embarrassing setbacks (killed programs, failed pills, and a GLP-1 opportunity it literally walked away from in the 1990s) Pfizer just dropped Phase 2 data for a monthly weight-loss injection that looks genuinely competitive. Not "nice try" competitive. Not "participation trophy" competitive. The kind of competitive that made Wall Street analysts sit up and start recalculating.
The drug is called PF-3944, and it just posted 12.3% placebo-adjusted weight loss at 28 weeks. That's after patients switched from weekly shots to just one injection per month. And the weight was still coming off, no plateau in sight.
In a market where Eli Lilly and Novo Nordisk have been running a two-horse race, Pfizer might have just bought a very expensive ticket to the starting gate.
One Shot a Month Changes the Math
Right now, if you're on Wegovy or Zepbound, you're injecting yourself every week. That's 52 needles a year. Some people don't mind. A lot of people do. And the ones who mind often stop, which is the dirty secret of the obesity drug boom. Adherence is a real problem when the treatment never ends.
PF-3944 flips the script. Patients in the VESPER-3 trial started with weekly injections for 12 weeks, a ramp-up period to build tolerance and get drug levels where they need to be. Think of it like preheating the oven. Then at week 12, they switched to a single monthly shot at a higher dose.
The result? The medium-dose group (4.8 mg monthly) lost 12.3% more body weight than placebo by week 28. The lower-dose group (3.2 mg monthly) hit 10%. Both results cleared the statistical bar with room to spare, p-values under 0.001.
For context, Novo Nordisk's semaglutide (the active ingredient in Wegovy) showed roughly 9% placebo-adjusted weight loss at the same 28-week mark in the landmark STEP-1 trial. PF-3944 is beating that number with a fraction of the injections.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
This is the detail that has analysts most intrigued. At week 28, the weight-loss curves for PF-3944 hadn't plateaued. They were still heading down.
Most GLP-1 drugs hit a ceiling at some point: the body adjusts, weight loss slows, and you settle into a new normal. The fact that PF-3944 patients were still losing weight at the primary endpoint suggests there's more to come. The trial runs to week 64, and full data will be presented at the American Diabetes Association meeting on June 6, 2026.
Pfizer is already planning to test a 9.6 mg monthly dose in Phase 3, double the medium dose from this trial. Internal modeling suggests that higher dose could push weight loss to around 16%. If that pans out, you're talking about territory that starts to rival Lilly's tirzepatide, the current king of the hill.
Pfizer's Long, Humbling Road to This Moment
To appreciate why these numbers matter, you need to understand just how badly Pfizer has stumbled in obesity.
Back in the late 1980s, Pfizer funded early GLP-1 research through a partnership with California Biotechnology. Then in 1991, it walked away, deciding the molecule wasn't viable. That's like selling your Apple stock in 1997. The GLP-1 class went on to become one of the biggest drug categories in history, and Pfizer watched from the sidelines.
More recently, Pfizer tried to develop danuglipron, an oral GLP-1 pill. The early versions had tolerability problems. A reformulated once-daily version looked more promising, but the program never caught fire the way competitors' drugs did. Two other internal obesity candidates were scrapped entirely.
So in late 2025, Pfizer did what companies do when their in-house efforts aren't cutting it: it bought someone else's work. The $10 billion acquisition of Metsera brought PF-3944 (originally called MET-097i) and three other clinical-stage obesity programs into Pfizer's portfolio. It was the most expensive admission ticket to the obesity race anyone had ever purchased.
These VESPER-3 results are the first real proof that the bet might pay off.
What the Analysts Are Saying
Wall Street's reaction has been a mixed cocktail of genuine optimism and careful hedging — like a poker player who drew a good hand but hasn't seen the river card yet.
BMO Capital Markets called the results "competitive." Evercore found them encouraging but noted they didn't quite match the earlier weekly-only data from Metsera, which had shown up to 14.1% placebo-adjusted loss. And Leerink pointed out that PF-3944's numbers in trial completers were slightly behind Lilly's Zepbound.
Pfizer's stock actually dipped about 4% when the data dropped, which tells you something about how high expectations have gotten in obesity. A drug that beats Wegovy's early benchmarks with monthly dosing and still-declining weight curves gets punished because it doesn't immediately threaten Zepbound's crown.
That said, the convenience angle is real. Monthly dosing isn't just a marketing gimmick. It's a genuine clinical differentiator in a disease that requires lifelong treatment. If you can get 85-90% of the weight loss with 75% fewer injections, a lot of patients, and a lot of doctors, will take that trade.
The Phase 3 Blitz Is Coming
Pfizer isn't tiptoeing into Phase 3. It's planning more than 10 late-stage trials launching throughout 2026, an absolute avalanche by industry standards.
The first, VESPER-4, is already enrolling patients for the weekly dosing version. VESPER-5 will test weekly dosing in patients with type 2 diabetes. VESPER-6 is the monthly dosing trial. At least seven more trials will target specific obesity-related conditions like heart disease and sleep apnea.
All told, Pfizer has over 20 obesity studies either running or planned. It's the kind of comprehensive program you build when you're betting a meaningful chunk of the company's future on a single therapeutic area.
The Bottom Line
Pfizer's safety data from VESPER-3 looked like what you'd expect from a GLP-1 drug: nausea, some vomiting, mostly mild or moderate. About 10 patients across the treatment arms dropped out due to side effects, split evenly between the weekly and monthly dosing periods. No dropouts in the placebo group.
Jim List, Pfizer's Chief Internal Medicine Officer, said the data "reinforces potential as a monthly treatment with competitive efficacy" and that the company is "positioned to address critical gaps in obesity care."
Is PF-3944 going to dethrone Zepbound tomorrow? No. Pfizer is years behind Lilly and Novo in getting an obesity drug to market, and Phase 3 trials take time. But monthly dosing is a card that nobody else at the table is playing right now. In a market projected to be worth over $100 billion, you don't need to win the whole pot. You just need a seat at the table and a hand worth playing.
Pfizer finally has both.
Deals & M&A
5 min read
Moderna Just Sold a Rare Disease Drug for Pennies on the Dollar
Moderna handed Recordati the commercial rights to a potentially first-in-class rare disease therapy for just $50 million upfront. Leerink analysts called it a "garage sale," and the math backs them up.
